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Introduction
Radical prostatectomy (RP) remains a standard 
of care therapy for clinically localized prostate 
cancer (PCa).1 However, the role of pelvic 
lymph node dissection (PLND) at the time of 
RP remains controversial, as its oncologic ben-
efit remains unclear.2–4 Moreover, significant 
variability exists among international guidelines 
regarding indications for PLND at the time of 
RP. The National Comprehensive Cancer 
Network (NCCN) and European Association of 
Urology (EAU) guidelines recommend per-
forming PLND for patients with ⩾2% and ⩾5% 
risk of pathological node positive (pN+) dis-
ease, respectively, whereas the American 
Urological Association (AUA) provides no 
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Abstract
Background: We examine the practical application of multiparametric MRI (mpMRI) prostate 
biopsy data using established pre-RP nomograms and its potential implications on RP 
intraoperative decision-making. We hypothesize that current nomograms are suboptimal in 
predicting outcomes with mpMRI targeted biopsy (TBx) data.
Materials and methods: Patients who underwent mpMRI-based TBx prior to RP were 
assessed using the MSKCC and Briganti nomograms with the following iterations: (1) Targeted 
(T) (targeted only), (2) Targeted and Systematic (TS) and (3) Targeted Augmented (TA) (targeted 
core data; assumed negative systematic cores for 12 total cores). Nomogram outcomes, 
lymph node involvement (LNI), extracapsular extension (ECE), organ-confined disease (OCD), 
seminal vesicle invasion (SVI), were compared across iterations. Clinically significant impact 
on management was defined as a change in LNI risk above or below 2% (Δ2) or 5% (Δ5).
Results: A total of 217 men met inclusion criteria. Overall, the TA iteration had more 
conservative nomogram outcomes than the T. Moreover, TA better predicted RP pathology for 
all four outcomes when compared with the T. In the entire cohort, Δ2 and Δ5 were 16.6–25.8% 
and 20.3–39.2%, respectively. In the subset of 190 patients with targeted and systematic cores, 
TA was a better approximation of TS outcomes than T in 71% (MSKCC) and 82% (Briganti) of 
patients.
Conclusion: In established pre-RP nomograms, mpMRI-based TBx often yield variable and 
discordant results when compared with systematic biopsies. Future nomograms must better 
incorporate mpMRI TBx core data. In the interim, augmenting TBx data may serve to bridge 
the gap.
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specific recommendations and suggests, based on 
expert opinion, that PLND be performed in 
patients with unfavorable intermediate- or high-
risk disease.5–7
Nevertheless, pre-RP nomograms have been 
designed to predict risk of lymph node involve-
ment (LNI), which in turn informs a surgeon’s 
decision to perform PLND.8,9 These nomograms 
were historically constructed to estimate LNI 
based on systematic 12-core prostate biopsies 
(PBx). With the introduction of multiparametric 
magnetic resonance imaging (mpMRI), cognitive 
or fusion targeted biopsies (TBx) have become 
increasingly prevalent, sometimes in the absence 
of traditional systematic biopsies (SBx). Current 
nomograms may not be applicable to men pre-
senting with TBx core data.10,11
Herein, we aimed to examine the practical appli-
cation of mpMRI TBx data using established pre-
RP nomograms and its potential implications on 
RP perioperative decision-making. We hypothe-
size that current pre-RP nomograms may be sub-
optimal in estimating the risk of LNI for men 
diagnosed with PCa via mpMRI TBx. 
Furthermore, we developed a novel method to 
‘augment’ mpMRI TBx cores to improve nomo-
gram outcome predictions to better identify 
appropriate candidates for PLND.
Methods
Following institutional review board approval 
(ref. #18D.597), retrospective chart review of a 
prospectively maintained RP database was con-
ducted at Thomas Jefferson University (TJU) and 
the University of Toronto (UT). All men with 
positive mpMRI TBx with available biopsy 
pathology from 2015 to 2018 were included. 
Positive mpMRI was inclusive of any lesions with 
a PI-RADS (Prostate Imaging–Reporting and 
Data System) score of 3–5. Standard PLND was 
completed in all men undergoing RP at TJU 
while standard PLND was completed selectively 
in men with ⩾2–5% risk of LNI at UT (surgeon 
preference). PBx pathology reports were 
abstracted for date of procedure, technique (tar-
geted or both targeted and systematic), and 
Gleason score (total and core level data). RP 
pathology synoptic reports were abstracted for 
date of procedure, completion of LND, T-stage, 
N-stage, final Gleason score, surgical margin sta-
tus, extracapsular extension (ECE), and seminal 
vesicle invasion (SVI). Organ confined disease 
(OCD) was defined as ⩽pT2N0 on RP pathol-
ogy. Age, race, clinical stage, and preoperative 
prostate-specific antigen (PSA) were also docu-
mented for all patients.
Two nomograms were utilized in this study: the 
Kattan Memorial Sloan Kettering Cancer Center 
(MSKCC) nomogram and the 2012 Briganti 
nomogram.8,9 Each patient was individually 
assessed with both nomograms using the follow-
ing iterations: (1) ‘Targeted’ (T), utilizing TBx 
core data only; (2) ‘Targeted and Systematic’ 
(TS), utilizing all available PBx core data; and (3) 
‘Targeted Augmented’ (TA), utilizing TBx core 
data alone while assuming negative remaining 
PBx cores for a total of 12 cores (Figure 1). 
Nomogram outputs were abstracted for each 
patient: LNI (Briganti) and OCD, ECE, LNI, 
SVI (MSKCC).
Mean ± standard deviation (SD) nomogram 
outcomes were compared between the T and 
TA iterations. Paired Student’s t test was uti-
lized to calculate statistical differences between 
the two iterations. All statistical tests were two-
tailed and a p value <0.05 was considered sta-
tistically significant. RP pathology was used to 
validate nomogram outcomes. Clinically signifi-
cant impact on management was defined as a 
change in risk above or below 2% (Δ2) or 5% 
(Δ5), based on current guidelines recommenda-




A total of 217 men met inclusion criteria. Of the 
159 men from UT, 90 (56.6%) underwent PLND, 
while all 58 men from the TJU cohort underwent 
standard PLND. Table 1 highlights key demo-
graphic data and preoperative parameters for the 
entire cohort and individual institutions. Of the 
190 patients who underwent both TBx and SBx, 
16 patients (8.4%) had discordant pathology: all 
16 demonstrated Gleason score upgrading on SBx 
cores when compared with TBx.
Nomogram and RP outcomes
In Table 2, the MSKCC and Briganti nomo-
gram risk outcomes were compared between the 
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T and TA iterations. Comparison of nomogram 
outcomes for individual cohorts are depicted in 
Supplementary Table 1A and 1B. On average, 
the TA iteration had more conservative 
nomogram predictions than the T iteration for 
all outcomes. These differences were statisti-
cally significant at p < 0.001 in both nomo-
grams at both institutions.
Figure 1. A sample patient who underwent MRI-US fusion targeted biopsy in addition to a 12-core systematic 
biopsy (total 16 cores) is depicted on the left. He had 2/12 cores positive on systematic biopsy and 3/4 cores 
positive on targeted biopsy. Biopsy core data was assessed according to the three iterations as depicted on 
the right.
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In only 21 (9.7%) cases, the TA iteration had 
worse LNI outcomes than the T iteration. Two of 
these patients had a higher percentage of positive 
cores on the TA iteration as they both had more 
than 12 targeted cores sampled on the initial 
biopsy. For the remaining 19 cases, we noted that 
all patients had 100% positive core involvement 
on their targeted cores alone, and only their 
MSKCC nomogram outcomes were affected.
Table 2 also depicts the comparison of nomo-
gram outcomes with final RP pathology. Risk of 
LNI was calculated in all patients who under-
went PLND while ECE, SVI, and OCD was cal-
culated for all patients regardless of whether 
PLND was performed. Comparison for nomo-
gram and RP outcomes for individual institu-
tions are depicted in Supplementary Table 1A 
and 1B. When compared with RP pathology, the 
TA iteration was a better approximation than 
the T iteration for LNI, ECE, SVI, and OCD in 
both nomograms.
Clinically significant impact on management
Table 3 represents patients whose risk of LNI 
crossed the 2% (Δ2) or 5% (Δ5) threshold across 
iterations. When comparing TA and T iterations, 
16.6–25.8% met Δ2 criteria and 20.3–39.2% met 
Δ5 criteria in the entire cohort. Of the 124 patients 
that underwent either Δ2/5 with the Briganti 
nomogram, 17 (13.7%) of them underwent both 
Δ2 and Δ5: 6 (35.0%) from the TJU cohort and 
11 (65.0%) from the UT cohort. No patients 
underwent both Δ2 and Δ5 with the MSKCC 
nomogram.
Utilizing the TS iteration as an internal 
validation
Finally, as an internal validation, in a subset of 
patients who underwent both SBx and TBx 
(n = 190), we compared their TA and T out-
comes to their TS outcomes for LNI risk. This 
data is depicted in Table 4. In both nomograms, 
the TA iteration was a better approximation to 
Table 1. Patient demographics.
Entire cohort TJU cohort UT cohort p value
Total number, n (%) 217 (100.0) 58 (26.7) 159 (73.3) –
Age, years (mean ± SD) 62.4 ± 6.5 61.5 ± 6.1 62.7 ± 6.7 0.230
PSA, ng/ml (mean ± SD) 8.6 ± 7.7 10.9 ± 10.7 7.7 ± 6.1 0.007
Clinical T stage, n (%) <0.001
cT1 138 (63.6) 50 (86.2) 88 (55.3)
cT2 77 (35.5) 7 (12.1) 70 (44.0)
cT3 2 (0.9) 1 (1.7) 1 (0.6)
Prostate biopsy technique, n (%) 0.572
Targeted only 27 (12.4) 6 (10.3) 21 (13.2)
Targeted and Systematic 190 (87.6) 52 (89.7) 138 (86.8)
Prostate biopsy grade group, n (%) 0.137
Grade group 1 50 (23.0) 8 (13.8) 42 (26.4)
Grade group 2 89 (41.0) 24 (41.4) 65 (40.9)
Grade group 3 45 (20.7) 13 (22.4) 32 (20.1)
Grade group 4 22 (10.1) 10 (17.2) 12 (7.5)
Grade group 5 11 (5.1) 3 (5.2) 8 (5.0)
PSA, prostate-specific antigen; TJU, Thomas Jefferson University; UT, University of Toronto.
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the patient’s TS outcomes than the T iteration in 
71–82% of cases.
Discussion
The addition of mpMRI as a diagnostic tool has 
allowed for better sampling and detection of clini-
cally significant PCa. mpMRI fusion TBx have 
become increasingly utilized in the diagnosis and 
surveillance of PCa. With multiple prospective 
studies now demonstrating its ability to better 
identify clinically significant PCa and limit identi-
fication of low-risk PCa,12–14 mpMRI fusion biop-
sies are now recommended by international 
guidelines in the setting of repeat biopsies and 
active surveillance.5,6,15,16 Indeed, the recent mul-
ticenter randomized controlled PRECISION trial 
demonstrated the superiority of mpMRI TBx over 
TRUS SBx in detecting PCa in biopsy-naïve 
men.13 Systematic reviews by Wu and Valerio also 
report the efficacy of mpMRI TBx over SBx.17,18 
However, while the optimism for TBx is high, it 
should be noted that SBx still identifies clinically 
significant PCa missed by TBx and mpMRI fusion 
biopsy outcomes are highly variable based on 
institution.12,19 As such, at this time, the general 
consensus is that TBx should be done in conjunc-
tion with SBx to maximize diagnostic yield.20




MSKCC (T) MSKCC (TA) Mean 
difference 
(SEL-ORIG)








LNI* 11.40 (10.62) 8.00 (8.61) –3.40 18.18 (17.29) 6.38 (9.83) –11.80 6.04†
ECE 59.61 (11.85) 53.10 (13.75) –6.52 – – – 42.40†
SVI 9.73 (9.28) 5.67 (7.04) –4.06 – – – 7.37†
OCD 38.64 (12.51) 45.38 (14.62) 6.75 – – – 54.84†
*Risk of LNI only includes patients who underwent PLND during RP (n = 148).
†TA is better than T in predicting RP pathology.
ECE, extracapsular extension; LNI, lymph node involvement; OCD, organ-confined disease; RP, radical prostatectomy; SD, standard deviation;  
SVI, seminal vesicle invasion; T, Targeted; TA, Targeted Augmented.
Table 3. Clinically significant impact on management between T and TA iteration.
MSKCC, n (%) Briganti, n (%) MSKCC, n (%) Briganti, n (%) MSKCC, n (%) Briganti, n (%)
Entire cohort T Bx only (n = 27) T+S Bx (n = 190) All Bx (n = 217)
 Δ2 3 (11.11) 3 (11.11) 33 (17.37) 53 (27.89) 36 (16.59) 56 (25.81)
 Δ5 4 (14.81) 9 (33.33) 40 (21.05) 76 (40.00) 44 (20.28) 85 (39.17)
TJU cohort T Bx only (n = 6) T+S Bx (n = 52) All Bx (n = 58)
 Δ2 1 (16.67) 1 (16.67) 4 (7.69) 18 (34.62) 5 (8.62) 19 (32.76)
 Δ5 1 (16.67) 2 (33.33) 14 (26.92) 20 (38.46) 15 (25.86) 22 (37.93)
UT cohort T Bx only (n = 21) T+S Bx (n = 138) All Bx (n = 159)
 Δ2 2 (9.52) 2 (9.52) 29 (21,01) 35 (25.36) 31 (19.50) 37 (23.27)
 Δ5 3 (14.29) 7 (33.33) 26 (18.84) 56 (40.58) 29 (18.24) 63 (39.62)
Bx, biopsy; T, Targeted; TJU, Thomas Jefferson University; T+S, Targeted and Systematic; UT, University of Toronto.
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With mpMRI serving as such an important bio-
marker for clinically significant PCa, there exists 
an urgent need to integrate mpMRI data into pre-
RP risk tools to improve patient stratification dur-
ing initial risk assessment.21,22 A recent study by 
Briganti and colleagues aimed to address this 
need by developing a novel nomogram that con-
siders relevant mpMRI data and clinical parame-
ters.23 These additional variables include clinical 
staging (OCD, ECE, SVI) on mpMRI, maximum 
lesion diameter and Gleason Grade Group on 
TBx. With an area under the receiver operating 
characteristic curve (AUC) of 0.84, their nomo-
gram demonstrated a higher net benefit com-
pared with the 2012 Briganti, 2017 Briganti, and 
MSKCC models, which are currently available 
models developed using standard biopsies 
alone.8,9,24 However, these results have yet to be 
validated.
As clinicians often use preoperative nomograms 
to complement their decision making to perform 
PLND during RP, practical utilization of these 
established pre-RP nomograms may be problem-
atic, especially in men presenting with only TBx 
cores. Therefore, we sought an intuitive way to 
incorporate targeted cores into current pre-RP 
nomograms when systematic cores are absent. As 
the number of TBx to a single region of interest 
ranges between 2 and 4,16,25 we developed a 
model to augment TBx core data to facilitate use 
of established pre-RP nomograms. This augmen-
tation is done by utilizing only the available 
targeted core data while assuming negative 
remaining biopsy cores for a total of 12 cores 
(Figure 1).
In our study, the predicted risk of LNI for TBx 
data after augmentation for the entire cohort 
(regardless of PLND) decreased by 2.85% and 
10.44% using the MSKCC and Briganti nomo-
grams, respectively (data not shown). More 
importantly, nomogram predictions after aug-
mentation of TBx data appears to be a closer 
approximation of the actual risk of LNI based on 
patients’ RP pathology (Table 2). Furthermore, 
with the MSKCC nomogram, utility of the TA 
iteration also better predicts ECE, OCD, and 
SVI.
Unlike the Briganti nomogram, biopsy core data 
is not required when estimating RP outcomes 
using the MSKCC nomogram.8,9 In cases where 
PBx data is absent, nomogram outcomes, after 
utilizing remaining preoperative parameters, are 
predicted based on the average value of the repre-
sented cohort within the database. As such, this 
may account for the reason why 19 patients had 
worse LNI outcomes predicted by the TA itera-
tion than the T iteration. Indeed, these actually 
reflect a systematic error in the MSKCC nomo-
gram, as patients with 100% positive core involve-
ment revert to nomogram outcomes that ignore 
core involvement altogether. Therefore, in these 
patients, these nomogram outcomes could not be 
interpreted accurately as the assumptions made 
Table 4. Approximation of TA and T iteration to the TS.
MSKCC, n (%) Briganti, n (%)
Entire cohort (n = 190) TA closer to TS 135 (71.1) 156 (82.1)
T closer to TS 34 (17.9) 18 (9.5)
No difference 21 (11.1) 16 (8.4)
TJU cohort (n = 52) TA closer to TS 25 (48.1) 35 (67.3)
T closer to TS 21 (40.4) 16 (30.8)
No difference 6 (11.5) 1 (1.9)
UT cohort (n = 138) TA closer to TS 110 (79.7) 121 (87.7)
T closer to TS 13 (9.4) 2 (1.5)
No difference 15 (10.9) 15 (10.9)
T, Targeted; TA, Targeted Augmented; TJU, Thomas Jefferson University; T+S, Targeted and Systematic; UT, University of 
Toronto.
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by the nomogram may not necessarily reflect the 
patient’s true outcome.
The consistent differences in nomogram out-
comes between the T and TA iterations question 
the application of pre-RP nomograms in patients 
who only undergo TBx. It also brings to the fore-
front whether PLND performed on these patients 
are justified. Aside from incurring higher costs 
and increased operative time, PLND completion 
may also increase complication risks. PLND at 
the time of RP is associated with pelvic lympho-
cele formation in 2–9% of patients.26 Other 
potential complications include lymphedema, 
venous thromboembolism, and injury to the ure-
ter or surrounding neurovasculature.27 From our 
results, 17–39% of patients who underwent 
PLND at the time of RP did not actually meet 
criteria for PLND based on current guideline rec-
ommendations after utility of the TA iteration.5,6
Despite the increased diagnostic yield of mpMRI 
fusion TBx, most patients still undergo SBx in 
addition to TBx. In our study, the TS iteration, 
which incorporates all available core data, most 
accurately reflects the true LNI risk in this patient 
population. When comparing TA or T with TS, 
we found that consideration of targeted cores 
only revealed suboptimal risk predictions, further 
justifying the need to consider systematic or aug-
mented cores in preoperative risk nomograms. 
Although the PROMIS trial reported mpMRI 
TBx having a higher sensitivity and negative pre-
dictive value than standard TRUS biopsies for 
detecting clinically significant PCa, its low speci-
ficity (41%) indicates that mpMRI is not a perfect 
discriminatory test.12 Moreover, results from the 
recently published ASIST trial demonstrated that 
mpMRI fusion TBx did not increase upgrading 
rates when compared with SBx alone, that both 
SBx and TBx missed significant cancer at almost 
equal rates, and that there are significant differ-
ences in TBx outcomes based on institution and 
level of expertise. The authors also suggested that 
patients with higher risk of disease should undergo 
SBx regardless of mpMRI findings.19 These stud-
ies further support the increasing evidence that 
SBx should be continued in addition to TBx.
We acknowledge that the study is not without its 
limitations. First, our study design was retrospec-
tive in nature with its inherent limitations. No 
central pathology review of PBx or RP pathology 
was utilized, though all were read and interpreted 
by experienced genitourinary pathologists. We 
also acknowledge that our concept of augmenting 
TBx data with negative systematic cores for a total 
of 12 cores may be flawed. First, the number of 
targeted cores obtained from each region of inter-
est may vary, thereby affecting the percentage of 
12 cores attributed to TBx and SBx. In addition, 
as PCa is known to be a multifocal disease, pre-
suming negative cores in the remainder of the 
prostate may artificially improve a patient’s risk 
profile; yet, patients only receiving TBx inherently 
have the risk of missed clinically significant PCa 
anyway. Finally, both nomograms utilized in our 
study were developed using distinctly different 
patient cohorts (different era of treatment, varia-
ble surgeon preferences, and techniques with 
regards to degree of lymph node dissection, etc.), 
which may impact nomogram accuracy.
Ultimately, however, the goal of this study was to 
highlight the drastic misrepresentation of disease 
burden in men who undergo TBx alone and the 
need for new nomograms that account for 
mpMRI TBx. In the interim, utilization of an 
augmented nomogram may help provide guid-
ance for surgical planning.
Conclusion
As mpMRI fusion biopsies become more com-
monplace in the diagnosis and management of 
PCa, there must be better incorporation of fusion 
biopsy data into future nomograms. TBx data, 
used in isolation in current nomograms, signifi-
cantly overestimate final pathology outcomes and 
cannot be used reliably. Augmentation with nega-
tive systematic cores may serve as a bridge in the 
interim to help guide surgical planning.
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